| Name | Thalidomide |
| Description | Thalidomide (Thalomid) is a synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. |
| In vitro | Thalidomide selectively inhibits the production of tumor necrosis factor-alpha (TNF-α) in human monocytes stimulated by lipopolysaccharides and other agonists. Its suppression of TNF-α is mediated through the enhancement of mRNA degradation. Moreover, thalidomide exerts a direct effect on MM cell lines by inducing apoptosis and G1 phase growth arrest, as well as on patient MM cells resistant to melphalan, doxorubicin hydrochloride, and dexamethasone. |
| In vivo | Administering 200mg/kg of Thalidomide resulted in the inhibition of vascularization in the corneal region within rabbits, with the inhibition rate ranging from 30% to 51% across three experiments. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 6.5 mg/mL (25.17 mM), Sonication is recommended.
|
| Keywords | TNF-α | Thalidomide | MolecularGlues | Molecular Glues | Ligands for E3 Ligase | LigandforE3Ligase | Ligand for E3 Ligase | Inhibitor | inhibit | E3 ligase-recruiting Moiety | Autophagy | Apoptosis |
| Inhibitors Related | Stavudine | Sodium 4-phenylbutyrate | L-Ascorbic acid | Hydroxychloroquine | Guanidine hydrochloride | L-Glutamic acid | Tributyrin | Valproic Acid | Paeonol | Naringin | L-Ascorbic acid sodium salt | Gefitinib |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
